Royalty Pharma plc's stocks have seen a variety of corporate actions and market reactions recently.
Geo Capital Gestora de Recursos Ltd and
Eventide Asset Management LLC have reduced their holdings, while firms like
Public Employees Retirement Association of Colorado increased their shares. Negative market sentiments erupted when
Cytokinetics sold a portion of its heart drug shares to Royalty Pharma and disrupted potential M&A prospects. Despite these fluctuations, the firm's stock performance remained decent and various financial institutions such as
Goldman Sachs and the
UBS Group have revised their investment stances on Royalty Pharma. The company has announced a dividend payout of $0.21 and also unveiled the pricing of $1.5 billion Senior Unsecured Notes. Royalty Pharma's Q1 earnings beat estimates, and increased investor confidence, contributing to new investments by firms like
ADAR1 Capital Management LLC. However, UBS also downgraded the stock to 'neutral'. Royalty Pharma ended the financial year with remarkable EPS growth, from US$0.098 in FY 2022 to US$2.54 in FY 2023.
Royalty Pharma Stocks News Analytics from Tue, 09 Jun 2020 07:00:00 GMT to Sun, 16 Jun 2024 11:23:27 GMT -
Rating 7
- Innovation 3
- Information 8
- Rumor -4
